Trametinib in Neurofibromatosis Type 1‐Associated Plexiform Neurofibroma—Real‐World Data From the SACHA‐France Study
Year: 2026
Type: article
Abstract: BACKGROUND: Neurofibromatosis type 1 (NF-1) frequently leads to inoperable, symptomatic plexiform neurofibromas (PNs) with limited therapeutic options. This study evaluates the real-world activity and safety of the MEK inhibitor trametinib in pediatric NF-1 patients with inoperable PNs in France. METHODS: We analyzed pediatric patients enrolled in the SACHA-France study (NCT04477681) who received trametinib for inoperable PNs between 01/2020 and 01/2026. Antitumor activity was evaluated by treating physicians using response evaluation criteria in solid tumors (RECIST) 1.1 criteria. Adverse events (AEs) were graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Clinical benefit data were collected retrospectively. RESULTS: Twenty-three patients (median age: 6 years [range: 0-17]) were included. Clinical benefit occurred in 87% (20/23), mainly through pain reduction (86% of symptomatic patients, 12/14). RECIST assessment showed partial response in 4% (1/23), stable disease in 87% (20/23), and progression in 9% (2/23). AEs occurred in 96% of patients, predominantly cutaneous (96%) and Grade 1-2. Four Grade 3 AEs were reported (osteitis, paronychia [n = 2], elevated creatine kinase), prompting discontinuation in 2 cases. Median treatment duration was 33 months [range: 1-58]. Treatment was discontinued in seven patients for prolonged stable disease, four for disease progression (two clinical, two radiological), two for severe AEs, and one for poor adherence. Nine patients remained on treatment at cutoff. CONCLUSION: Trametinib provided notable clinical benefit and disease stabilization in pediatric NF-1-associated PNs, despite limited RECIST-defined tumor shrinkage. The safety profile was manageable and consistent with known data. Comparative studies with other MEK inhibitors are warranted to optimize treatment strategies.
Source: Pediatric Blood & Cancer
Authors: Clara Rigaud Vanderkelen, Isabelle Aerts, François Sevrin, Lee Aymar Ndounga‐Diakou, Samuel Abbou, Yves Reguerre, Natacha Entz‐Werle, Camille Khanfar, Pierre Leblond, Cécile Faure‐Conter, Liana Carausu, Stéphane Ducassou, Claire Freycon, Anne Pagnier, Gilles Vassal, Pablo Berlanga, Nicolas Andre
Institutions: Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Inserm, Université Paris Sciences et Lettres, Institut Curie, Centre Oscar Lambret, Université Paris-Saclay, Institut Gustave Roussy, Centre Hospitalier Universitaire de La Réunion, Hôpitaux Universitaires de Strasbourg, Centre Hospitalier Universitaire Amiens-Picardie, Institut d’Hématologie et d’Oncologie Pédiatrique, Centre Léon Bérard, Centre Hospitalier Régional Universitaire de Brest, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier Universitaire de Grenoble, Centre National de la Recherche Scientifique, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7235415992
